Loading stock research
Loading stock research…
No token price observed
Observation time unavailableUnavailable
Underlying share reference$51.02(Jupiter stock data)
A reference quote for WGS, not a price you can trade the token at.
Updated · Source: Jupiter stock data
Buy from your own wallet on Solana mainnet. You review and sign every transaction.
Checking whether mainnet purchases are available…
You sign in your own wallet. Ovelo never holds your keys or funds.
Daily closes of WGS, the underlying share. A token’s rights, price and liquidity can differ from the share.
Research observed · Source: Yahoo Finance, Wikipedia (CC BY-SA)
What you would hold, where it trades and where these numbers come from.
Observation time unavailableUnavailable
The company behind WGS.
GeneDx is an American biotechnology company specializing in genomic diagnostics, with a focus on whole genome sequencing (WGS) and whole exome sequencing (WES) for the diagnosis of rare and inherited disorders. The company provides genetic testing services to healthcare providers, hospitals, and health systems, and contributes to advancements in genomic medicine through research, biopharma partnerships, and advocacy. The company is headquartered in Stamford, Connecticut, with its clinical laboratory in Gaithersburg, Maryland, and is publicly traded on the Nasdaq under the ticker symbol WGS. GeneDx was founded in 2000 by Sherri Bale and John Compton, scientists from the National Institutes of Health (NIH), to provide diagnostic services for patients with rare and ultra-rare disorders. The company was acquired by BioReference Laboratories in 2006 and subsequently by Sema4 in 2022, after which it underwent a strategic transformation refocusing on whole exome and genome sequencing in pediatrics and changed its name to GeneDx. Since launching exome testing in 2011, the company has built GeneDx Infinity, a rare disease dataset including more than one million clinically sequenced…
Observed · Source: Company profile
Momentum from daily closes of the underlying share.
Computed from daily closes of the underlying share, not the token. Not a recommendation.
Close of · Source: Yahoo Finance daily closesStale
Reported financials. They describe the company, not the token’s market value.
| Item | Period end | Value |
|---|---|---|
| Revenue (annual) | 31 Dec 2025 | $427.54M |
| Revenue (annual) | 31 Dec 2024 | $305.45M |
| Revenue (annual) | 31 Dec 2023 | $202.57M |
| Revenue (annual) | 31 Dec 2022 | $234.69M |
| Net income (annual) | 31 Dec 2025 | −$21.02M |
| Net income (annual) | 31 Dec 2024 | −$52.29M |
| Net income (annual) | 31 Dec 2023 | −$175.77M |
| Net income (annual) | 31 Dec 2022 | −$548.98M |
| Diluted EPS (annual) | 31 Dec 2025 | −0.73 USD/share |
| Diluted EPS (annual) | 31 Dec 2024 | −1.94 USD/share |
| Diluted EPS (annual) | 31 Dec 2023 | −7.23 USD/share |
| Diluted EPS (annual) | 31 Dec 2022 | −53.63 USD/share |
| Total assets (annual) | 31 Dec 2025 | $523.71M |
| Total assets (annual) | 31 Dec 2024 | $419.38M |
| Total assets (annual) | 31 Dec 2023 | $418.76M |
| Total assets (annual) | 31 Dec 2022 | $490.94M |
| Total debt (annual) | 31 Dec 2025 | $113.17M |
| Total debt (annual) | 31 Dec 2024 | $117.38M |
| Total debt (annual) | 31 Dec 2023 | $119.27M |
| Total debt (annual) | 31 Dec 2022 | $77.13M |
| Operating cash flow (annual) | 31 Dec 2025 | $33.28M |
| Operating cash flow (annual) | 31 Dec 2024 | −$28.50M |
| Operating cash flow (annual) | 31 Dec 2023 | −$180.15M |
| Operating cash flow (annual) | 31 Dec 2022 | −$319.16M |
| Free cash flow (annual) | 31 Dec 2025 | $14.26M |
| Free cash flow (annual) | 31 Dec 2024 | −$33.99M |
| Free cash flow (annual) | 31 Dec 2023 | −$185.86M |
| Free cash flow (annual) | 31 Dec 2022 | −$333.48M |
| Revenue (quarterly) | 30 Sept 2026 | $123.10M |
| Revenue (quarterly) | 30 Jun 2026 | $114.44M |
| Revenue (quarterly) | 31 Mar 2026 | $102.25M |
| Revenue (quarterly) | 31 Dec 2025 | $120.99M |
| Revenue (quarterly) | 30 Sept 2025 | $116.74M |
| Net income (quarterly) | 30 Sept 2026 | −$12.33M |
| Net income (quarterly) | 30 Jun 2026 | −$17.74M |
| Net income (quarterly) | 31 Mar 2026 | −$63.32M |
| Net income (quarterly) | 31 Dec 2025 | −$17.67M |
| Net income (quarterly) | 30 Sept 2025 | −$7.64M |
| Diluted EPS (quarterly) | 30 Sept 2026 | −0.41 USD/share |
| Diluted EPS (quarterly) | 30 Jun 2026 | −0.60 USD/share |
| Diluted EPS (quarterly) | 31 Mar 2026 | −2.16 USD/share |
| Diluted EPS (quarterly) | 30 Sept 2025 | −0.27 USD/share |
| Diluted EPS (quarterly) | 30 Jun 2025 | 0.36 USD/share |
Reported dividends, splits and filings, each linked to its source.
No dividends, splits or filings were found.
Recent headlines about the company.